Clinical trial
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
NCT02504645 is registered in ClinicalTrials.gov with ImmuPharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
- Lead sponsor
- ImmuPharma
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2015
- Completion date
- January 31, 2018
- Enrollment
- 202 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.